Thus, increased type I/II interferons released from the immune compartment (likely from T cells and macrophages) following LNP-CTNNB1 treatment are engaging with macrophages in the TIME milieu, and in part contributing towards polarizing them towards a pro-inflammatory anti-tumor phenotype. This evidence concerns the gene CTNNB1 and neoplasm.